Aarti Drugs Ltd.
11 May 2015
Available for Immediate Download
Aarti Drugs Ltd. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Aarti Drugs Ltd. required for business and competitor intelligence needs - Intelligence on Aarti Drugs Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Aarti Drugs Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Aarti Drugs (ADL) is pharmaceutical company, engaged in the manufacturing of vitamins, anti-arthritis, anti-fungal, antibiotics and angiotensin converting enzyme (ACE) inhibitors. The company also manufactures anti-diabetics, anti-cholinergic, sedatives and anti-depressant drugs. ADL primarily operates in India, where it is headquartered in Mumbai. The company recorded revenues of INR9,699.4 million (approximately $161.4 million) in the fiscal year ended March 2014, an increase of 17.6% over 2013. The company's operating profit was INR1,182.5 million (approximately $19.7 million) in fiscal 2014, an increase of 25.3% over 2013. Its net profit was INR617.1 million (approximately $10.3 million) in fiscal 2014, an increase of 36.4% over 2013. Reasons to Purchase: - Gain understanding of Aarti Drugs Ltd. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Aarti Drugs Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Aarti Drugs Ltd. your competitors' business structure, strategy and prospects